Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Nicholas P Giustini

2PUBLICATIONS

8CO-AUTHORS

Predictive and prognostic markersMolecular targets

Featured researcher

Get your video featured.

Publish with JoVE

Featured researcher

Get your video featured.

Publish with JoVE

Publications (2)

Sort by Publication Date:

|Jul 11, 2024

<i>EGFR</i> V834L and L858R Comutation Is Associated With Response to Osimertinib in Non-Small-Cell Lung Cancer.

Nicholas P Giustini, Colin C Pritchard, Nikhil V Kamat

|Aug 11, 2022

Resistance to EGFR Tyrosine Kinase Inhibitor Therapy in Non-Small-Cell Lung Cancer via Newly Acquired Targetable Oncogenic Driver Alterations With an Emphasis on <i>BRAF</i>: Case Series and Literature Review of Treatment.

Nicholas P Giustini, Sandip Pravin Patel, Nathaniel J Myall

Pageof 1

Frequent Collaborators

1 joint publications

José Fernando do Prado Moura

1 joint publications

Amit Kulkarni

1 joint publications

Richard C Chao

1 joint publications

Heather Wakelee

1 joint publications

Lyudmila Bazhenova

1 joint publications

Colin C Pritchard

1 joint publications

Nikhil V Kamat

1 joint publications

Manoj P Menon

Frequent Collaborators

1 joint publications

José Fernando do Prado Moura

1 joint publications

Amit Kulkarni

1 joint publications

Richard C Chao

1 joint publications

Heather Wakelee

Top Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on : Jun 26, 2019

See more related videos

Top Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on : Jun 26, 2019

See more related videos